RedoxTherapies' Acquisition

RedoxTherapies was acquired by Juno Therapeutics on July 14, 2016.

RedoxTherapies is a company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibit…

Articles about RedoxTherapies' Acquisition: